Startup Fundraising•

Altesa BioSciences Raises $75M for COPD Drug Development

Altesa BioSciences secures $75M Series B funding from Forbion, Sanofi, Medicxi, and Pitango to advance its rhinovirus therapy for COPD exacerbations.

Share:
AM
Alvaro de la Maza

Partner at Aninver

Stay ahead of the market

Get instant notifications when new news matching "this topic" are published.

Analysis

Altesa BioSciences has successfully closed an oversubscribed $75 million Series B financing round, signaling strong investor confidence in its novel approach to treating respiratory conditions. The substantial capital infusion is earmarked to advance its lead candidate, vapendavir, a first-in-class therapy targeting rhinovirus-induced inflammation in patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and asthma.

The funding round was spearheaded by prominent life sciences investor Forbion, with significant participation from established players including Sanofi, Medicxi, and Pitango. This collective backing from a consortium of experienced healthcare investors underscores the perceived potential of Altesa's platform to address a critical unmet need in respiratory medicine. The company's focus on rhinovirus, a common trigger for exacerbations in COPD patients, positions it to potentially disrupt current treatment paradigms.

Central to Altesa's development pipeline is the ongoing Phase 2b CARDINAL trial. This pivotal study is enrolling approximately 900 COPD patients across the United States and the United Kingdom. The trial is designed to rigorously evaluate the efficacy and safety of vapendavir in mitigating rhinovirus-driven exacerbations, a major cause of morbidity and healthcare utilization in the COPD population. Top-line results from the CARDINAL trial are anticipated in the second quarter of 2026.

The market for COPD therapeutics is substantial and growing, driven by an aging global population and increasing prevalence of risk factors such as smoking and air pollution. Current treatments primarily focus on symptom management and reducing the frequency of exacerbations, but a therapy that directly targets a key viral trigger like rhinovirus could offer a significant advancement. The global COPD market is projected to reach tens of billions of dollars in the coming years, highlighting the immense commercial opportunity for effective new treatments.

Dr. Brett Giroir, CEO of Altesa BioSciences, emphasized the therapeutic rationale, stating that the company's strategy directly addresses the viral component responsible for significant inflammatory responses in vulnerable COPD patients. By intervening early in the viral infection cycle, Altesa aims to prevent the cascade of inflammation that leads to debilitating exacerbations, thereby improving patient outcomes and potentially reducing hospitalizations.

The successful completion of this Series B round provides Altesa BioSciences with the necessary runway to complete its crucial Phase 2b trial and prepare for subsequent development stages. The involvement of strategic investors like Sanofi also hints at potential future collaborations or acquisition opportunities as the company progresses through clinical development. This financing event is a strong indicator of the continued investor appetite for innovative biopharmaceutical companies tackling complex diseases with differentiated therapeutic strategies.